Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
Onishi
Sachiko
S
Yoshio
Taku
T
Nagashima
Takao
T
Minota
Seiji
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000627:therapeutic use*; D007075:Immunoglobulin M / Q000097:blood; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D015415:Biomarkers; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010456:Peptides, Cyclic; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; C487763:cyclic citrullinated peptide; D000069283:Rituximab; D000068800:Etanercept; D008727:Methotrexate